Table of Contents
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
6. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE
6.1. Overview
6.2. Conventional TACE
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
6.3. DEB-TACE
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
7. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION
7.1. Overview
7.2. Unresectable HCC
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
7.3. Early-Stage HCC
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
8. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE
8.1. Overview
8.2. Chemotherapeutic Agents
8.2.1. Doxorubicin
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
8.2.2. Cisplatin
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
8.2.3. Mitomycin
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
8.2.4. Others
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
8.3. Radiotherapeutic Agents
8.3.1. Yttrium-90 microspheres
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
8.3.2. Iodine-131 lipiodol
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
8.3.3. Rhenium-188 lipiodol
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
8.3.4. Phosphorus-32 Glass Microspheres
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
8.3.5. Holmium-166 Chitosan Complex
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
8.3.6. Others
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
8.4. Drug-eluting Particles
8.4.1. Polyvinyl Alcohol Microspheres
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
8.4.2. Polymer Microspheres
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
8.5. Others
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
9. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER
9.1. Overview
9.2. Hospitals & Clinics
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
9.3. Cancer Research Centers
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
9.4. Others
Market Estimates & Forecast, by Region, 2023-2032
Market Estimates & Forecast, by Country, 2023-2032
10. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY REGION
10.1. Overview
10.2. Americas
10.2.1. North America
10.2.1.1. US
10.2.1.2. Canada
10.2.2. Latin America
10.3. Europe
10.3.1. Western Europe
10.3.1.1. Germany
10.3.1.2. France
10.3.1.3. Italy
10.3.1.4. Spain
10.3.1.5. UK
10.3.1.6. Rest of Western Europe
10.3.2. Eastern Europe
10.4. Asia-Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle East & Africa
10.5.1. Middle East
10.5.2. Africa
11. COMPANY LANDSCAPE
11.1.1. Overview
11.1.2. Competitive Analysis
12. COMPANY PROFILES
12.1. Advaxis Inc.
12.1.1. Company Overview
12.1.2. Product Type Overview
12.1.3. Financial Overview
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. Baxter
12.2.1. Company Overview
12.2.2. Product Type Overview
12.2.3. Financial Overview
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3. Bellicum Pharmaceuticals, Inc.
12.3.1. Company Overview
12.3.2. Product Type Overview
12.3.3. Financial Overview
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. Boston Scientific Corporation
12.4.1. Company Overview
12.4.2. Product Type Overview
12.4.3. Financial Overview
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. Cook
12.5.1. Company Overview
12.5.2. Product Type Overview
12.5.3. Financial Overview
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6. Hikma Pharmaceuticals PLC
12.6.1. Company Overview
12.6.2. Product Type Overview
12.6.3. Financial Overview
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. Isofol Medical AB
12.7.1. Company Overview
12.7.2. Product Type Overview
12.7.3. Financial Overview
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. Nippon Kayaku Co., Ltd.
12.8.1. Company Overview
12.8.2. Product Type Overview
12.8.3. Financial Overview
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
12.9. Novartis
12.9.1. Company Overview
12.9.2. Product Type Overview
12.9.3. Financial Overview
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.9.6. Key Strategies
12.10. Pfizer
12.10.1. Company Overview
12.10.2. Product Type Overview
12.10.3. Financial Overview
12.10.4. Key Developments
12.10.5. SWOT Analysis
12.10.6. Key Strategies
12.11. Sirtex SIR-Spheres Pty Ltd.
12.11.1. Company Overview
12.11.2. Product Type Overview
12.11.3. Financial Overview
12.11.4. Key Developments
12.11.5. SWOT Analysis
12.11.6. Key Strategies
12.12. Spectrum Pharmaceuticals, Inc.
12.12.1. Company Overview
12.12.2. Product Type Overview
12.12.3. Financial Overview
12.12.4. Key Developments
12.12.5. SWOT Analysis
12.12.6. Key Strategies
12.13. Others
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SYNOPSIS, 2023-2032
TABLE 2 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET ESTIMATES & FORECAST, 2023-2032 (USD MILLION)
TABLE 3 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2023-2032 (USD MILLION)
TABLE 4 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)
TABLE 5 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)
TABLE 6 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 7 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY REGION, 2023-2032 (USD MILLION)
TABLE 8 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2023-2032 (USD MILLION)
TABLE 9 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)
TABLE 10 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)
TABLE 11 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 12 US: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY DRUG CLASS, 2023-2032 (USD MILLION)
TABLE 13 US: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)
TABLE 14 US: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)
TABLE 15 US: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 16 CANADA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2023-2032 (USD MILLION)
TABLE 17 CANADA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)
TABLE 18 CANADA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)
TABLE 19 CANADA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 20 LATIN AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2023-2032 (USD MILLION)
TABLE 21 LATIN AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)
TABLE 22 LATIN AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)
TABLE 23 LATIN AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 24 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2023-2032 (USD MILLION)
TABLE 25 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)
TABLE 26 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)
TABLE 27 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 28 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2023-2032 (USD MILLION)
TABLE 29 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)
TABLE 30 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)
TABLE 31 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 32 EASTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2023-2032 (USD MILLION)
TABLE 33 EASTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)
TABLE 34 EASTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)
TABLE 35 EASTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 36 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2023-2032 (USD MILLION)
TABLE 37 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)
TABLE 38 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)
TABLE 39 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PROCEDURE TYPE, 2023-2032 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY INDICATION, 2023-2032 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY PRODUCT TYPE, 2023-2032 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET, BY END USER, 2023-2032 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET
FIGURE 4 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY PROCEDURE TYPE, 2020 (%)
FIGURE 5 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY INDICATION, 2020 (%)
FIGURE 6 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY PRODUCT TYPE, 2020 (%)
FIGURE 7 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY END USER, 2020 (%)
FIGURE 8 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY REGION, 2020 (%)
FIGURE 7 AMERICAS: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE BY REGION, 2020 (%)
FIGURE 9 NORTH AMERICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 10 EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY REGION, 2020 (%)
FIGURE 11 WESTERN EUROPE: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 12 ASIA-PACIFIC: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 13 MIDDLE EAST & AFRICA: TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET SHARE, BY COUNTRY, 2020 (%)
FIGURE 14 GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION (TACE) MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
FIGURE 15 ADVAXIS INC.: KEY FINANCIALS
FIGURE 16 ADVAXIS INC. SEGMENTAL REVENUE
FIGURE 17 ADVAXIS INC.: REGIONAL REVENUE
FIGURE 18 BAXTER: KEY FINANCIALS
FIGURE 19 BAXTER: SEGMENTAL REVENUE
FIGURE 20 BAXTER: REGIONAL REVENUE
FIGURE 21 BELLICUM PHARMACEUTICALS, INC.: KEY FINANCIALS
FIGURE 22 BELLICUM PHARMACEUTICALS, INC.: SEGMENTAL REVENUE
FIGURE 23 BELLICUM PHARMACEUTICALS, INC.: REGIONAL REVENUE
FIGURE 24 BOSTON SCIENTIFIC CORPORATION: KEY FINANCIALS
FIGURE 25 BOSTON SCIENTIFIC CORPORATION: SEGMENTAL REVENUE
FIGURE 26 BOSTON SCIENTIFIC CORPORATION: REGIONAL REVENUE
FIGURE 27 COOK: KEY FINANCIALS
FIGURE 28 COOK: SEGMENTAL REVENUE
FIGURE 29 COOK: REGIONAL REVENUE
FIGURE 30 HIKMA PHARMACEUTICALS PLC: KEY FINANCIALS
FIGURE 31 HIKMA PHARMACEUTICALS PLC: SEGMENTAL REVENUE
FIGURE 32 HIKMA PHARMACEUTICALS PLC: REGIONAL REVENUE
FIGURE 33 ISOFOL MEDICAL AB: KEY FINANCIALS
FIGURE 34 ISOFOL MEDICAL AB: SEGMENTAL REVENUE
FIGURE 35 ISOFOL MEDICAL AB: REGIONAL REVENUE
FIGURE 36 NIPPON KAYAKU CO., LTD.: KEY FINANCIALS
FIGURE 37 NIPPON KAYAKU CO., LTD.: SEGMENTAL REVENUE
FIGURE 38 NIPPON KAYAKU CO., LTD.: REGIONAL REVENUE
FIGURE 39 NOVARTIS: KEY FINANCIALS
FIGURE 40 NOVARTIS: SEGMENTAL REVENUE
FIGURE 41 NOVARTIS: REGIONAL REVENUE
FIGURE 42 PFIZER: KEY FINANCIALS
FIGURE 43 PFIZER: SEGMENTAL REVENUE
FIGURE 44 PFIZER: REGIONAL REVENUE
FIGURE 45 SIRTEX SIR-SPHERES PTY LTD.: KEY FINANCIALS
FIGURE 46 SIRTEX SIR-SPHERES PTY LTD.: SEGMENTAL REVENUE
FIGURE 47 SIRTEX SIR-SPHERES PTY LTD.: REGIONAL REVENUE
FIGURE 48 SPECTRUM PHARMACEUTICALS, INC.: KEY FINANCIALS
FIGURE 49 SPECTRUM PHARMACEUTICALS, INC.: SEGMENTAL REVENUE
FIGURE 50 SPECTRUM PHARMACEUTICALS, INC.: REGIONAL REVENUE
